Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 8/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | APOL1 | O14791 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.31 |
| ▸ | CA2 | P00918 | 3/20 | 0.31 |
| ▸ | ACHE | P22303 | 3/20 | 0.31 |
| ▸ | TLR4 | O00206 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5006986 | 1.00 | MTNR1A (0.37) | MTNR1AMTNR1BTHRBAPOL1CA1 | |
| SCHEMBL5091076 | 1.00 | MTNR1A (0.37) | MTNR1AMTNR1BTHRBAPOL1CA1 | |
| SCHEMBL23881931 | 0.88 | THRB (0.46) | THRBCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3485253 | 0.88 | THRB (0.46) | THRBCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL743138 | 0.86 | EPHX1 (0.36) | TLR4CYP3A4CYP2C19 | |
| SCHEMBL3221585 | 0.86 | THRB (0.41) | THRBCYP3A4 | |
| SCHEMBL2634531 | 0.81 | — | — | |
| SCHEMBL4420636 | 0.81 | MTNR1A (0.56) | MTNR1AMTNR1BTHRBCA1CA2 | |
| SCHEMBL31551125 | 0.81 | MTNR1A (0.36) | MTNR1AMTNR1BTHRBAPOL1CA1 | |
| Acetic Acid SCHEMBL28266825 | 0.81 | TLR4 (0.37) | MTNR1AMTNR1BTHRBTLR4CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4277893-A1 | INDOLE DERIVATIVES AS KINASE INHIBITORS | GB005, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-20230174481-A1 | KINASE INHIBITORS | VIDYA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-11572364-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220409593-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS | 2022-12-29 | — | — | US | disclosed |
| WO-2022155111-A1 | INDOLE DERIVATIVES AS KINASE INHIBITORS | GB005, INC. (US) | 2022-07-21 | — | — | WO | disclosed |
| US-11059826-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-07-13 | — | — | US | disclosed |
| US-11046699-B2 | Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses | RAPT THERAPEUTICS, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3802544-A1 | PYRAZOLO-PYRIMIDIN-AMINO-CYCLOALKYL COMPOUNDS AND THEIR THERAPEUTIC USES | RAPT Therapeutics, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3784669-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2021-03-03 | — | — | EP | disclosed |
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2019-10-24 | — | — | US | disclosed |
| US-20080153851-A1 | Cycloalkyl Piperidine Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572364-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | MTNR1A 461/4885MTNR1B 332/4885THRB 2102/4885 |
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | MTNR1A 461/4885MTNR1B 332/4885THRB 2102/4885 |
| US-11059826-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | MTNR1A 461/4885MTNR1B 332/4885THRB 2102/4885 |
| US-11046699-B2 | Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses | GLS, GLS2, TK2 | MTNR1A 1831/4885MTNR1B 1212/4885THRB 1910/4885 |
| US-20230174481-A1 | KINASE INHIBITORS | BTK, LYN, LCK | MTNR1A 4361/4885MTNR1B 4177/4885THRB 1591/4885 |
| US-20220409593-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PSEN1, PSEN2 | MTNR1A 2203/4885MTNR1B 2082/4885THRB 3445/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | MTNR1A 461/4885MTNR1B 332/4885THRB 2102/4885 |
| US-20080153851-A1 | Cycloalkyl Piperidine Tachykinin Receptor Antagonists | TACR1, TACR2, NPSR1 | MTNR1A 388/4885MTNR1B 265/4885THRB 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.